Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Niagen Bioscience, Inc. (NAGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NAGE (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.4
1 Year Target Price $11.4
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 102.65% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 836.53M USD | Price to earnings Ratio 59 | 1Y Target Price 11.4 |
Price to earnings Ratio 59 | 1Y Target Price 11.4 | ||
Volume (30-day avg) 4 | Beta 1.95 | 52 Weeks Range 3.10 - 14.69 | Updated Date 05/24/2025 |
52 Weeks Range 3.10 - 14.69 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.18 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate - | Actual 0.0418 |
Profitability
Profit Margin 13.07% | Operating Margin (TTM) 15.66% |
Management Effectiveness
Return on Assets (TTM) 12.21% | Return on Equity (TTM) 33.47% |
Valuation
Trailing PE 59 | Forward PE 65.36 | Enterprise Value 743633586 | Price to Sales(TTM) 7.75 |
Enterprise Value 743633586 | Price to Sales(TTM) 7.75 | ||
Enterprise Value to Revenue 6.89 | Enterprise Value to EBITDA 50.62 | Shares Outstanding 78769696 | Shares Floating 51792712 |
Shares Outstanding 78769696 | Shares Floating 51792712 | ||
Percent Insiders 34.44 | Percent Institutions 30.6 |
Upturn AI SWOT
Niagen Bioscience, Inc.
Company Overview
History and Background
Niagen Bioscience, Inc., founded with a focus on nicotinamide riboside (NR) research and development, aimed to commercialize NR as a dietary supplement to support cellular health. Over time, it has grown to explore various applications and formulations.
Core Business Areas
- Nutraceuticals: Development and sale of nicotinamide riboside (NR) supplements under various brand names. Products are aimed at improving cellular energy, healthy aging and overall wellness.
Leadership and Structure
Information on specific leadership and organizational structure is limited. Typically, such companies would have a CEO, CFO, and other key executives managing research, development, marketing, and sales.
Top Products and Market Share
Key Offerings
- Niagen (Nicotinamide Riboside) Supplements: Sold as dietary supplements. Information on market share and specific revenue is not publicly available. Competitors include other companies offering NAD+ boosting supplements.
Market Dynamics
Industry Overview
The nutraceutical industry is experiencing growth, driven by increased consumer interest in health and wellness and scientific advancements. The market is highly competitive with numerous players.
Positioning
Niagen Bioscience, Inc. positioned itself as a pioneer in the NR space, building a brand around its patented NR formulation. The main advantage is being the first to market a specific molecule.
Total Addressable Market (TAM)
The global dietary supplements market is expected to reach hundreds of billions of dollars in the coming years. Niagen Bioscience, Inc. targets a portion of this market with its NR products but its current TAM remains unclear.
Upturn SWOT Analysis
Strengths
- Early mover advantage in NR market
- Patented NR formulation (Niagen)
- Brand recognition among early adopters
Weaknesses
- Limited publicly available financial data
- Small Company with limited resources
- Lack of product diversification
Opportunities
- Expanding NR applications through research
- Partnering with larger companies for distribution
- Developing new NR-based products or formulations
Threats
- Increased competition from other NR and NAD+ boosting supplements
- Regulatory changes affecting supplement industry
- Questions about long-term safety and efficacy of NR
Competitors and Market Share
Key Competitors
- TRIM
- NOW
- NATR
Competitive Landscape
Niagen Bioscience, Inc.'s success depends on differentiating itself through scientific validation, brand building, and effective marketing. Competitors will seek to undercut the companies NR product and target other parts of the market. Market share data is difficult to ascertain due to the breadth of companies.
Growth Trajectory and Initiatives
Historical Growth: Insufficient data is publicly available to assess historical growth trends.
Future Projections: Projections for future growth unavailable as the company is not publicly traded.
Recent Initiatives: Information is limited; typically includes research partnerships, product development, and marketing campaigns.
Summary
Niagen Bioscience, Inc. has a strong position as an early mover in the NR supplement market. However, the company faces increasing competition and needs to continue innovation and differentiate itself. Due to limitations of publicly available information, the company strength and potential are difficult to evaluate from the given data. Its the need to expand the distribution network or to get acquired.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company information, Market research reports, Industry analysis
Disclaimers:
The analysis is based on limited publicly available data and general market knowledge. Financial figures are estimates. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Niagen Bioscience, Inc.
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2008-07-15 | CEO & Director Mr. Robert N. Fried | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://www.niagenbioscience.com |
Full time employees 104 | Website https://www.niagenbioscience.com | ||
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.